Oak Thistle LLC Takes Position in Danaher Co. (NYSE:DHR)

Oak Thistle LLC acquired a new stake in Danaher Co. (NYSE:DHR – Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,451 shares of the conglomerate’s stock, valued at approximately $363,000.

Several other hedge funds have recently modified their holdings of the stock. Patrick M Sweeney & Associates Inc. grew its position in Danaher by 3.4% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 1,230 shares of the conglomerate’s stock valued at $307,000 after acquiring an additional 40 shares in the last quarter. Trust Co of Kansas raised its stake in shares of Danaher by 4.1% during the second quarter. Trust Co of Kansas now owns 1,022 shares of the conglomerate’s stock valued at $255,000 after buying an additional 40 shares during the period. Abacus Planning Group Inc. boosted its stake in Danaher by 0.7% in the second quarter. Abacus Planning Group Inc. now owns 5,439 shares of the conglomerate’s stock valued at $1,359,000 after purchasing an additional 40 shares during the period. ST Germain DJ Co. Inc. raised its stake in Danaher by 1.4% in the first quarter. ST Germain DJ Co. Inc. now owns 2,880 shares of the conglomerate’s stock valued at $719,000 after purchasing an additional 41 shares during the period. Finally, Premier Path Wealth Partners LLC boosted its stake in shares of Danaher by 1.8% in the second quarter. Premier Path Wealth Partners LLC now owns 2,345 shares of the conglomerate’s stock valued at $586,000 after purchasing an additional 42 shares during the period. Institutional investors own 79.05% of the company’s shares.

Analyst upgrades and downgrades

A number of analysts recently weighed in on the company. Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. TD Cowen boosted their price objective on Danaher from $290.00 to $310.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Leerink Partners boosted their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a research note on Wednesday, July 24th. Evercore ISI decreased their price target on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research note on Tuesday, July 2nd. Finally, Barclays upped their target price on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Moderate Buy” and an average target price of $278.94, according to MarketBeat.com.

Check out our latest report on DHR

Insider buying and selling

In related news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available via this link. In related news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at approximately $1,130,374.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available via this link. Also, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the sale, the chief financial officer now owns 29,407 shares of the company’s stock, valued at $8,229,254.88. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 39,659 shares of company stock worth $11,042,433. 11.10% of shares are owned by corporate insiders.

Danaher price performance

Shares of NYSE:DHR opened at $273.09 on Tuesday. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43, and a quick ratio of 1.04. The company has a fifty day moving average price of $261.87 and a 200 day moving average price of $255.96. The company has a market cap of $197.23 billion, a PE ratio of 46.29, a PEG ratio of 4.38 and a beta of 0.83.

Danaher (NYSE:DHR – Get Free Report ) last posted its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share for the quarter, topping the consensus estimate of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.59 billion. In the same period last year, the company earned $2.05 per share. The company’s revenue fell 2.9% year over year. As a group, equities analysts expect Danaher Co. to post 7.59 EPS for the current fiscal year.

Danaher Company Profile

(Free Report)

Danaher Corporation designs, manufactures and markets professional, medical, industrial and commercial products and services worldwide. The Biotechnology segments provide bioprocess technologies, consumables and services that advance, accelerate and integrate drug development and manufacturing; cell line and cell culture media development services; cell culture media, process fluids and manufacturing buffers, chromatography resins, filtration technologies, aseptic fill finishing; disposable hardware and supplies and services such as design and installation of complete manufacturing suites; laboratory filtration, separation and purification; laboratory-scale protein purification and analytical tools; reagents, membranes and services; and filtration solutions for health care.

Recommended articles

Want to see what other hedge funds own DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Danaher Co. (NYSE:DHR – Free Report).

Get news and reviews for Danaher Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Danaher and related companies with MarketBeat.com’s FREE daily email newsletter.